CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	12 Months Ended
	May. 31, 2015	May. 31, 2014
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (331,410)	$ (215,660)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	253,275	207,033
Change in provision for allowance for doubtful accounts	(12,532)	(85,730)
Inventory reserve	(18,222)	(35,591)
Gain on disposal of property and equipment	(665)	(1,200)
Stock option expense	10,016	11,003
Decrease in deferred rent liability	(20,406)	(13,799)
Increase in deferred tax assets	(298,000)	(217,000)
Changes in assets and liabilities:
Accounts receivable	348,667	(490,316)
Inventories	(243,378)	(158,960)
Prepaid expenses and other	(60,780)	93,106
Other assets	(20,541)	35,091
Accounts payable and other accrued expenses	(29,136)	103,563
Accrued compensation	17,631	(93,813)
Net cash used in operating activities	(405,481)	(862,273)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(10,503)	(137,234)
Purchases of intangible assets	(14,179)	(146,496)
Proceeds from sales of property and equipment	1,900	1,200
Net cash used in investing activities	$ (22,782)	(282,530)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock		150,000
Proceeds from exercise of stock options	$ 9,560	35,275
Net cash provided by financing activities	9,560	185,275
Effect of exchange rate changes on cash	(2,115)	(1,143)
Net decrease in cash and cash equivalents	(420,818)	(960,671)
CASH AND CASH EQUIVALENTS, beginning of year	1,509,125	2,469,796
CASH AND CASH EQUIVALENTS, end of year	$ 1,088,307	1,509,125
Non-cash investing and financing activities:
Payment of international regulatory approval fees in Exchange for $100,000 due on agreement to purchase Biomerica restricted stock		100,000
Cash paid during the period for:
Interest	$ 138	$ 142
Income taxes	$ 800